LakeShore Biopharma Co., Ltd Cash Flow Conversion Efficiency
LakeShore Biopharma Co., Ltd cash flow conversion efficiency. Based on the latest financial reports, LakeShore Biopharma Co., Ltd (LSBCF) has a cash flow conversion efficiency ratio of -0.001x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-693.96K) by net assets ($1.27 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of LakeShore Biopharma Co., Ltd (2021–2025)
Cash flow conversion efficiency of LakeShore Biopharma Co., Ltd from 2021 to 2025. This chart illustrates how LakeShore Biopharma Co., Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LSBCF stock price and chart for real-time trading data and today's change.
LakeShore Biopharma Co., Ltd Cash Flow Conversion Ratio Explained
LakeShore Biopharma Co., Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
LakeShore Biopharma Co., Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LakeShore Biopharma Co., Ltd ranked by their cash flow conversion efficiency. Also see market cap of LakeShore Biopharma Co., Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arkadia Digital Media Tbk PT
JK:DIGI
|
0.084x |
|
Rincon Resources Ltd
AU:RCR
|
-0.029x |
|
Conico Ltd
AU:CNJ
|
-0.265x |
|
Dolphin International Bhd
KLSE:5265
|
-0.004x |
|
Tartana Minerals Ltd
AU:TAT
|
-0.217x |
|
Global Sukses Solusi Tbk PT
JK:RUNS
|
-0.002x |
|
Australian Silica Quartz Group Ltd
F:4B4
|
-0.076x |
|
Unity Biotechnology Inc
NASDAQ:UBX
|
31.010x |
Annual Cash Flow Conversion Efficiency for LakeShore Biopharma Co., Ltd (2021–2025)
The table below shows the annual cash flow conversion efficiency of LakeShore Biopharma Co., Ltd from 2021 to 2025. Review LakeShore Biopharma Co., Ltd (LSBCF) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $499.75 Million | $-120.98 Million | -0.242x | +52.01% |
| 2024-03-31 | $585.21 Million | $-295.23 Million | -0.504x | -101.40% |
| 2023-03-31 | $728.45 Million | $-182.47 Million | -0.250x | +73.92% |
| 2022-03-31 | $180.68 Million | $-173.55 Million | -0.961x | +99.99% |
| 2021-03-31 | $21.36K | $-246.61 Million | -11543.271x | -- |
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS… Read more